Demographic, biological and radiographic data for the patients with early rheumatoid arthritis
| Patients (n=566) | Patients without RRP at 1 year (n=421) | Patients with RRP at 1 year (n=145) | p Value | |
|---|---|---|---|---|
| Demographic data | ||||
| Age, median (IQR) | 50.5 (40.2–57.0) | 49.9 (40.0–56.7) | 52.4 (41.7–58.6) | NS |
| Women, n (%) | 445 (78.6) | 336 (79.8) | 109 (75.2) | NS |
| Smokers, n (%) | 272 (48.1) | 204 (48.5) | 68 (46.9) | NS |
| Disease duration in months, median (IQR) | 5.0 (3.1–7.4) | 4.8 (3.0–7.1) | 5.2 (3.5–7.8) | NS |
| Biological data | ||||
| ESR, mm/1 h, median (IQR) | 22 (12–37) | 20 (12–34) | 27 (14–49) | 0.0063 |
| CRP level, mg/L, median (IQR) | 9 (0–21) | 8 (0–18) | 14 (5–36) | <0.0001 |
| ≥1 allele encoding HLADRB1 SE, n (%) | 292 (54.0%) | 205 (50.9) | 87 (63.0) | 0.0133 |
| RF+, n (%) | 307 (54.2) | 208 (49.4) | 99 (68.3) | <0.0001 |
| Anti-CCP2 titres, n (%) | <0.0001 | |||
| Negative | 295 (52.1) | 242 (57.5) | 53 (36.5) | |
| Low | 11 (1.9) | 6 (1.4) | 5 (3.4) | |
| High | 260 (45.9) | 173 (41.1) | 87 (60.0) | |
| Anti-MCV titres, n (%) | <0.0001 | |||
| Negative | 268 (47.3) | 217 (51.5) | 51 (35.2) | |
| Low | 51 (9.0) | 44 (10.4) | 7 (4.8) | |
| High | 247 (43.6) | 160 (38.0) | 87 (60.0) | |
| AhFibA titres, n (%) | <0.0001 | |||
| Negative | 272 (48.1) | 225 (53.4) | 47 (32.4) | |
| Low | 30 (5.3) | 20 (4.8) | 10 (6.9) | |
| High | 264 (46.6) | 176 (41.8) | 88 (60.7) | |
| Radiographic data | ||||
| Baseline mTSS, median (IQR) | 3 (0–7) | 2 (0–7) | 3 (0–8) | NS |
| mTSS at 1 year, median (IQR) | 6 (2–12) | 4 (2–8) | 13 (8–19) | <0.0001 |
| mTSS progression, median (IQR) | 2 (0–5) | 0 (0–2) | 8 (6–11) | <0.0001 |
| Baseline therapeutic data | ||||
| Steroids | 71 (12.5) | 51 (12.1) | 20 (13.8) | NS |
| Year 1 therapeutic data | ||||
| Steroids | 259 (45.8) | 190 (45.4) | 69 (47.6) | NS |
| Any DMARDs | 436 (82.4) | 315 (80.2) | 121 (89.0) | 0.020 |
| Biologics | 40 (7.1) | 30 (7.1) | 10 (6.9) | NS |
AhFibA, antihuman citrullinated fibrinogen antibodies; anti-CCP2, anticyclic citrullinated peptides generation 2 antibodies; anti-MCV, antimutated citrullinated vimentine antibodies; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; mTSS, van der Heijde modified total sharp score; DMARDs, disease modifying antirheumatic drugs; RF, rheumatoid factor; RRP, rapid radiographic progression; SE, presence of at least one allele of the shared epitope of HLA-DRB1.